IVD Medical Holding

What IVD Medical Holding does

IVD Medical Holding (华检医疗控股有限公司 / ETHK Labs Inc., 01931.HK) is a Hong Kong-listed public company that operates as an AI medical capital operations platform structured around three business curves. K1 (IVD Distribution Network) is the foundational cash-generating engine, comprising the exclusive national distribution of Sysmex coagulation products in China since 1997 through subsidiary Weishida (威士达), reaching 1,711 tertiary hospitals across all 31 Chinese provinces via 236 direct customers and 1,073 distributors, and holding 31.2% of China's coagulation IVD primary distribution market with 6,600+ installed analyzers generating over RMB 200 million in annual net profit. K2 (Huajian Ecosystem) is a horizontal R&D-manufacturing-sales-service integrated platform aggregating 20+ domestic IVD companies with proprietary IP and 6 international brands across POCT, mass spectrometry, molecular diagnostics, microbiology, biochemistry, and immunology, encompassing 500+ IVD products.

The company pursues an explicit M&A-as-growth strategy, acquiring and integrating AI medical segment champions globally under a 'high-tech, globalization, large asset' screening framework, then deploying proprietary K1-K2-K3 value amplification. K3 (Capital Operations) encompasses M&A funds, structured financing, asset securitization, IP tokenization, and stablecoin operations via US-based ETHK BANK Inc. Notable 2025 transactions include the RMB 500 million acquisition of a controlling stake in medical IT leader Chuangye Huikang (300451.SZ), which provides BsoftGPT medical LLM capabilities, 300 million health records, and 100 million electronic medical records; the USD 1.5 billion RWA tokenization partnership with Transcenta Holding (06628.HK); and acquisitions of Xingzai Times (liquid cooling) and Huajian Zhizao (microbiology automation). The company is also pursuing a Nasdaq dual listing and has accumulated ETH as a treasury asset.

Go-to-market relies on B2B distribution through direct hospital relationships and a tiered distributor network, with no consumer-facing channels; revenue mechanics derive from distribution commissions on Sysmex products and increasingly from M&A-driven IP monetization, algorithm-based revenue sharing (planned for Chuangye Huikang's SaaS pivot), and capital operations income. The customer base is concentrated in Chinese tertiary hospitals, with strategic expansion into US operations targeting capital markets, digital assets, and cross-border medical IP.

Name

IVD Medical Holding

Legal name

华检医疗控股有限公司 ETHK Labs Inc.

Website

https://ivdholding.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

IVD Medical Holding (ETHK Labs Inc., 01931.HK) is a Hong Kong-listed AI medical capital operations platform that uses M&A to acquire and integrate AI healthcare assets, anchored by exclusive Chinese distribution of Sysmex coagulation products reaching 1,711 tertiary hospitals and complemented by ecosystem, IP tokenization, and stablecoin operations.

Ownership category

akta.pro rank

Product category

AI Medical Capital Operations

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Healthcare Provider ERP (Hospital Operations, Supply Chain, Finance) (HDAEAEAH), Evaluation, Benchmarking & Observability (Evals, Monitoring, Tracing) (HDAAACAH)

Keywords

• In vitro diagnostics
• Medical capital operations
• Diagnostic equipment distribution
• AI medical platforms
• Clinical diagnostic services

Headquarters

HQ city

Sha Tin

HQ country

Hong Kong SAR China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. IVD Distribution (K1): IVD product distribution generating stable cash flows. The company distributes Sysmex coagulation products as exclusive national distributor since 1997, with subsidiary 威士达 holding dominant market position. Generates over RMB 200 million annual net profit to fund M&A activities.
2. Capital Operations (K3): Proprietary IP monetization and capital operations including strategic M&A funds, structured financing, asset securitization, and cross-border capital cooperation. Creates value discovery and liquidity channels for medical IP assets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

IVD Medical Holding operates an AI medical capital operations platform that combines exclusive IVD product distribution (Sysmex coagulation products in China since 1997) with M&A-driven integration of AI medical companies. The company applies a three-curve value amplification framework (K1 IVD distribution, K2 ecosystem collaboration, K3 capital operations) to acquire, integrate, and amplify the value of global AI medical champions. Its nationwide IVD distribution network reaching 1,711 tertiary hospitals provides market access for acquired companies, while capital operations include IP securitization, RWA tokenization, and stablecoin operations through ETHK BANK Inc.

Product overview

IVD Medical Holding (华检医疗控股有限公司, ETHK Labs Inc., 01931.HK) operates as an AI medical capital operations platform built on three mutually reinforcing business curves. K1 (IVD Distribution Network) is the foundational cash-generating engine — the exclusive national distributor of Sysmex coagulation products since 1997, with a network covering all 31 Chinese provinces, reaching 1,711 tertiary hospitals through 236 direct customers and 1,073 distributors. K2 (ETHK Ecosystem) is a horizontal '研产销服' (R&D-manufacturing-sales-service) integrated platform linking 20+ domestic IVD companies with 6 international brands across POCT, mass spectrometry, molecular diagnostics, microbiology, and immunology. K3 (Capital Operations) is the value-creation engine — encompassing M&A funds, structured financing, IP securitization, and stablecoin operations via ETHK BANK — that amplifies K1 and K2 assets into capital market returns. Key ecosystem members include Chuangye Huikang (healthcare IT, 300451.SZ, acquired 2025), Xingzai Times (AI compute liquid cooling), Huajian Zhizao (microbiology automation), and Carbonhua Detection (molecular diagnostics). The group also developed a Nipah virus detection dual-platform solution and is pursuing a U.S. dual listing on Nasdaq.

Differentiator

Problem solved

Functional benefit

Brands

• 华检生态圈 (Huajian Ecosystem): IVD industry first integrated platform connecting 20+ domestic IVD companies with proprietary IP and 6 international brands, covering POCT, mass spectrometry, molecular diagnostics, microbiology, biochemistry, immunology with 500+ IVD products
• 三大曲线 (Three Curves/K1-K2-K3)
• BsoftGPT
• LARK Series
• ETHK链上金融生态

Products and services

• IVD Distribution Network (K1) Nationwide IVD product distribution network serving as the foundational cash-flow engine of the group, with 236 direct hospital customers and 1,073 distributors reaching 1,711 tertiary hospitals across China. Provides market entry channels and rapid clinical integration for acquired AI medical companies, distributing Sysmex coagulation and blood-cell analyzers plus a portfolio of 500+ IVD products from 20+ domestic IVD companies and 6 international brands.
• ETHK Ecosystem (K2) Integrated R&D-manufacturing-sales-service (研产销服) platform linking 20+ domestic IVD companies with proprietary IP and 6 international brands across POCT, mass spectrometry, molecular diagnostics, microbiology, biochemistry, and immunology, covering 500+ IVD products. Functions as an IP aggregation and member-company collaboration hub for acquired subsidiaries and partner firms.
• Capital Operations Services (K3) Capital operations platform encompassing strategic M&A funds, structured financing, asset securitization (including RWA tokenization of medical IP), and cross-border capital cooperation. Provides value-verification and liquidity channels for frontier medical IP assets; ETHK BANK Inc. (Colorado) serves as the operational vehicle for stablecoin licensing and IP tokenization initiatives.
• LARK Series Automated Microbial Sample Preprocessing System Fully automated clinical microbiology sample preprocessing system developed by subsidiary Huajian Zhizao that addresses a domestic gap in the most labor-intensive and biosafety-risk-heavy step of microbiology testing. Backed by 30+ IP assets including 2 invention patents.
• Single-Phase Immersion Liquid Cooling Solutions High-density computing liquid cooling solution with full-stack self-developed capabilities covering cooling fluids, thermal management algorithms, and monitoring systems. Achieves PUE below 1.1, providing critical AI compute infrastructure within the ETHK ecosystem.
• Nipah Virus Detection Dual-Platform Solution Dual-platform diagnostic solution for Nipah virus developed by a subsidiary of IVD Medical, demonstrating rapid-response capability in emerging infectious disease diagnostics and marking a milestone in the AI medical strategy upgrade announced in 2026.

Quantifiable outcome

• 42% improvement in early diagnosis/treatment rates in pilot hospitals using AI patient tracking system (APTS)

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered flagship, core and minor.

• Chuangye Huikang (创业慧康, 300451.SZ)flagshipStrategic or Co-development Partner · 1 November 2025Acquired controlling stake (RMB 500M for 6.23% + voting rights to 12.64%) becoming largest shareholder. Goal: transform into 'China's first AI medical listed company' by upgrading business from project-based to SaaS subscription and algorithm profit-sharing, from software vendor to AI platform and data asset operator.
• ETHK BANK Inc.coreOthers · 13 October 2025Wholly-owned subsidiary registered in Colorado, USA as global headquarters for K3 capital operations. Manages USD 4.365M US property acquisition, stablecoin license applications, and IP tokenization initiatives.
• Guofu Quantum Innovation (国富量子创新有限公司)minorStrategic or Co-development Partner · 13 October 2025Disclosed transaction that subsequently expired/lapsed according to company announcements.
• Transcenta Holding (创胜集团, 06628.HK)flagshipStrategic or Co-development Partner · 22 September 2025Strategic cooperation agreement involving USD 1.5 billion RWA tokenization of innovative drug pipeline assets. IVD Medical provides capital operations expertise while Transcenta contributes biotech IP for tokenization on blockchain.
• Renhe Pharmaceutical (仁和药业, 000650.SZ) - Renhe InternationalcoreStrategic or Co-development Partner · 16 September 2025Major strategic cooperation with Renhe Pharmaceutical's wholly-owned subsidiary for AI medical ecosystem development.
• HashKey GroupcoreStrategic or Co-development Partner · 10 August 2025Global strategic cooperation framework agreement for digital asset treasury strategies and cryptocurrency integration into medical capital operations.
• Huada Win-Win (华大共赢)coreStrategic or Co-development Partner · 30 July 2025Strategic cooperation for ecosystem development and shared growth in medical/health sectors.
• Sysmex (希森美康)flagshipChannel Partner/ Reseller/ Distributor · 1 January 1997Exclusive national distributor of Sysmex coagulation products in China since 1997. Sysmex also became shareholder in subsidiary 威士达, deepening strategic alliance.

Scale indicators10 records

Recent moves9 records

Expansion highlights7 records

Broad incumbents

• Sysmex Corporation: Japan-based global IVD leader and IVD Medical's principal upstream partner for coagulation products since 1997. Highly comparable as it operates in the same IVD/coagulation segment, though as a manufacturer and global player rather than China-focused distributor.
• Mindray Medical: China's largest medical device and IVD manufacturer with broad product portfolio including IVD reagents, hematology, and coagulation analyzers. Comparable as a Chinese IVD ecosystem incumbent competing across overlapping product categories, though at vastly greater scale and as a manufacturer rather than distributor.

Emerging players

• iCarbonX: China-based AI-driven precision health and biological data platform founded by Jun Wang. Comparable as an emerging Chinese AI medical data company pursuing ecosystem-based value creation — partial thematic overlap with IVD Medical's K2/K3 strategy.

Direct peers

• Autobio Diagnostics: China-based IVD manufacturer covering microbiology, immunoassay, and clinical chemistry. Comparable as a Chinese IVD product manufacturer that could serve as a K2 ecosystem member given IVD Medical's distribution network.
• BGI Genomics: China-based genomics and molecular diagnostics leader with hospital channel access and AI/data capabilities. Comparable as a Chinese diagnostics company combining IVD/molecular diagnostics with data-driven health technology positioning.
• Winning Health Technology: Chinese healthcare IT company providing hospital information systems and EHR platforms with deep hospital penetration. Closely comparable to Chuangye Huikang's hospital IT business, and a potential direct competitor as IVD Medical repositions Chuangye Huikang as an AI medical platform.
• Da An Gene (DA Gene): Sun Yat-sen University-affiliated Chinese IVD manufacturer with broad IVD reagent portfolio including molecular diagnostics. Comparable as a Chinese IVD ecosystem member potentially suited to integration into IVD Medical's K2 ecosystem.
• Yidu Tech: Chinese healthcare AI and medical data platform that monetizes clinical data assets and serves medical institutions. Comparable as a Chinese AI medical data-asset operator — directly overlapping with IVD Medical's BsoftGPT/APTS and Chuangye Huikang positioning.
• KingMed Diagnostics: China's largest independent medical diagnostics laboratory network with extensive hospital relationships. Comparable as a Chinese diagnostics platform leveraging hospital channels, though focused on lab services rather than IVD product distribution.

Others

• HashKey Group: Hong Kong-based digital asset and cryptocurrency financial services group with which IVD Medical has a strategic cooperation agreement. Comparable as an enabler/partner in IVD Medical's K3 capital operations, stablecoin, and RWA tokenization strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IVD Medical Holding